GR1803 + anti-CD38 monoclonal antibody

**GR1803 + anti-CD38 monoclonal antibody** is a combination therapy under clinical investigation for the treatment of multiple myeloma. GR1803 is an experimental agent administered in combination with an anti-CD38 monoclonal antibody—a class that includes approved antibodies such as daratumumab and isatuximab. The anti-CD38 monoclonal antibody targets the CD38 antigen, which is highly expressed on multiple myeloma cells, and works primarily by inducing tumor cell death via immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), direct apoptosis, and immunomodulation. The goal of this combination is to enhance antitumor efficacy by leveraging both the novel mechanism of GR1803 and the cytotoxic and immunomodulatory properties of the anti-CD38 antibody[1][2][3][5].